These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20816079)

  • 1. Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.
    Ozer N; Schiffer CA; Haliloglu T
    Biophys J; 2010 Sep; 99(5):1650-9. PubMed ID: 20816079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
    Nalam MN; Ali A; Altman MD; Reddy GS; Chellappan S; Kairys V; Ozen A; Cao H; Gilson MK; Tidor B; Rana TM; Schiffer CA
    J Virol; 2010 May; 84(10):5368-78. PubMed ID: 20237088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.
    Das D; Koh Y; Tojo Y; Ghosh AK; Mitsuya H
    J Chem Inf Model; 2009 Dec; 49(12):2851-62. PubMed ID: 19928916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV-1 protease: the rigidity perspective.
    Heal JW; Jimenez-Roldan JE; Wells SA; Freedman RB; Römer RA
    Bioinformatics; 2012 Feb; 28(3):350-7. PubMed ID: 22291339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.
    Weber IT; Waltman MJ; Mustyakimov M; Blakeley MP; Keen DA; Ghosh AK; Langan P; Kovalevsky AY
    J Med Chem; 2013 Jul; 56(13):5631-5. PubMed ID: 23772563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease.
    King NM; Prabu-Jeyabalan M; Bandaranayake RM; Nalam MN; Nalivaika EA; Özen A; Haliloğlu T; Yilmaz NK; Schiffer CA
    ACS Chem Biol; 2012 Sep; 7(9):1536-46. PubMed ID: 22712830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.
    Blum A; Böttcher J; Dörr S; Heine A; Klebe G; Diederich WE
    J Mol Biol; 2011 Jul; 410(4):745-55. PubMed ID: 21762812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.
    Velazquez-Campoy A; Muzammil S; Ohtaka H; Schön A; Vega S; Freire E
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):311-28. PubMed ID: 14754432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.
    Ghosh AK; Brindisi M; Nyalapatla PR; Takayama J; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem; 2017 Oct; 25(19):5114-5127. PubMed ID: 28434781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
    Ghosh AK; Williams JN; Ho RY; Simpson HM; Hattori SI; Hayashi H; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2018 Nov; 61(21):9722-9737. PubMed ID: 30354121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
    Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
    Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
    J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.